In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252211869 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marta Budzińska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics Polish Academy of Sciences, 60-479 Poznan, Poland. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Induced Pluripotent Stem Cells, Genetic Therapy, Dystrophin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre.
Abstract (Originalsprache)
Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by disruptions in the dystrophin gene. This study aims to investigate potential a therapeutic approach using genetically modified human iPS-derived mesoangioblast-like cells (HIDEMs) in mdx mouse model. This study utilizes patient-specific myoblasts reprogrammed to human induced pluripotent stem cells (iPSCs) and then differentiated into HIDEMs. Lentiviral vectors carrying microdystrophin sequences have been employed to deliver the genetic construct to express a shortened, functional dystrophin protein in HIDEMs. The study indicated significant changes within redox potential between healthy and pathological HIDEM cells derived from DMD patients studied by catalase and superoxide dismutase activities. Microdystrophin expressing HIDEMs also improved expression of genes involved in STARS (striated muscle activator of Rho signaling) pathway albeit in selective DMD patients (with mild phenotype). Although in vivo observations did not bring progress in the mobility of mdx mice with HIDEMs, microdystrophin interventions this may argue against “treadmill test” as suitable for assessment of mdx mice recovery. Low-level signaling of the Rho pathway and inflammation-related factors in DMD myogenic cells can also contribute to the lack of success in a functional study. Overall, this research contributes to the understanding of DMD pathogenesis and provides insights into potential novel therapeutic strategy, highlighting the importance of personalized gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Human Genetics Polish Academy of Sciences, 60-479 Poznan, Poland.
ORCID-Profile: Agnieszka Malcher, Agnieszka Zimna, Maciej Kurpisz
Förderung
- National Science Centre
Zitieren
APA
Budzińska, M., Malcher, A., Zimna, A., & Kurpisz, M. (2024). In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252211869
Vancouver
Budzińska M, Malcher A, Zimna A, Kurpisz M. In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252211869
BibTeX
@article{Budziska2024,
author = {Budzińska, Marta and Malcher, Agnieszka and Zimna, Agnieszka and Kurpisz, Maciej},
title = {In Vitro Gene Therapy Using Human iPS-Derived Mesoangioblast-Like Cells (HIDEMs) Combined with Microdystrophin (μDys) Expression as the New Strategy for Duchenne Muscular Dystrophy (DMD) Experimental Treatment},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252211869}
}
EUVIMED